Clinical Trial Update: Follow-up Data of Patients Treated With XIGRIS® in France

View source ↗

Summary

Follow-up data from a France-based clinical study evaluating XIGRIS (drotrecogin alfa (activated)) in patients with sepsis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis

Drugs mentioned

• Xigris (Drotrecogin alfa (activated))

Snippet

Sponsor: Eli Lilly and Company | Conditions: Sepsis | Status: COMPLETED